EMA Authorised: Nivestim (filgrastim) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA has authorized Nivestim (filgrastim) from Pfizer Europe MA EEIG as a biosimilar to treat neutropenia in cancer patients and in the context of hematopoietic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neutropenia

Drugs mentioned

• Nivestim (filgrastim)

Snippet

Status: Authorised. Therapeutic area: Hematopoietic Stem Cell Transplantation;Cancer. MAH: Pfizer Europe MA EEIG. Decision date: 12/02/2026